论文部分内容阅读
目的:评价孟鲁司特联合血塞通片对慢性阻塞性肺疾病(COPD)稳定期患者的生活质量影响。方法:按照预先制定的COPD患者入选及排除标准选择60例患者,采用孟鲁司特联合血塞通片治疗,治疗前及治疗终点采用呼吸系统疾病专用的St.George’s呼吸问卷(SGRQ)量化评分,比较治疗前后评分变化,并对患者治疗前后SGRQ评分结果进行配对t检验及多变量相关性分析,评价患者在用药前后生存质量变化。结果:由配对t检验看出,P值均小于0.05,表明第一部分评分(呼吸症状)、第二部分评分(活动受限、疾病影响)、总评分这三个治疗前后评分差均有统计学意义;将第一部分评分、第二部分评分、总评分这三个治疗前后评分进行多变量方差分析,结果P值均小于0.01,患者治疗前后SGRQ评分差异存在统计学意义。结论:孟鲁司特联合血塞通片对提高COPD稳定期患者的生存质量有较好影响。
Objective: To evaluate the impact of montelukast and Xuesaitong Tablet on the quality of life in patients with stable chronic obstructive pulmonary disease (COPD). METHODS: Sixty patients were selected according to pre-established criteria for inclusion and exclusion of patients with COPD and treated with montelukast and Xuesaitong tablets. The patients were treated with respiratory disease-specific St. George’s Respiratory Questionnaire (SGRQ) before and at the end of treatment The changes of scores before and after treatment were compared. The results of paired t-test and multivariate analysis of SGRQ scores before and after treatment were used to evaluate the quality of life of patients before and after treatment. Results: The paired t test showed that the P values were less than 0.05, indicating that the first part of the score (respiratory symptoms), the second part of the score (limited mobility, the impact of disease), the total score of the three before and after treatment were statistically significant differences Significance; the first part of the score, the second part of the score, the total score of the three before and after treatment scores were analyzed by multivariate analysis of variance, the results were less than 0.01 P value SGRQ score before and after treatment there was a statistically significant difference. Conclusion: Montelukast combined with Xuesaitong tablet can improve the quality of life of patients with stable COPD.